| 19.63 Real-Time Quote |  -0.13 / -0.66%Today’s Change | 10.85 Today|||52-Week Range 20.75 | +63.00% Year-to-Date |
| Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner C... Jun 18 / Benzinga | Bausch & Lomb - successful outcome May 27 / FT.com |
| Actavis-Medicines360 Ink Partnership - Analyst Blog Jun 13 / Zacks.com | Valeant pays $8.7 billion for Bausch & Lomb May 27 / CNNMoney.com |
| Warner Chilcott: Should You Buy Joel Greenblatt's Latest Pick? Jun 13 / MotleyFool.com | Actavis: The latest Fortune 500 company to "leave" the U.S. for tax reasons May 21 / Fortune |
| Actavis Challenges Patents - Analyst Blog Jun 10 / Zacks.com | Actavis/Warner Chilcott: simple medicine May 20 / FT.com |
| Pharma M&A: defensive deals May 28 / FT.com | The biggest merger you didn't hear about today May 20 / Fortune |
| Previous close | 19.76 |
| Today’s open | 19.74 |
| Day’s range | 19.45 - 19.82 |
| Volume | 3,261,184 |
| Average volume (3 months) | 6,878,908 |
| Market cap | $5.0B |
| Dividend yield | 2.55% |
| Earnings growth (last year) | +140.30% |
| Earnings growth (this year) | -18.20% |
| Earnings growth (next 5 years) | +1.00% |
| Revenue growth (last year) | -6.86% |
| P/E ratio | -- |
| Price/Sales | 1.18 |
| Price/Book | -- |
| Today’s change | Today’s % change | |
|---|---|---|
| IDXXIDEXX Laboratories I... | -1.08 | -1.19% |
| ENDPEndo Health Solution... | -0.14 | -0.36% |
| SLXPSalix Pharmaceutical... | -0.04 | -0.06% |
| JAZZJazz Pharmaceuticals... | -0.98 | -1.41% |
| Next reporting date | August 9, 2013 |
| EPS forecast (this quarter) | $0.85 |
| Annual revenue (last year) | $2.5B |
| Annual profit (last year) | $403.0M |
| Net profit margin | 15.86% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
President, Chief Executive Officer & Director Roger M. Boissonneault |
Chief Financial Officer, Director & Executive VP Paul S. Herendeen, MBA |
Corporate headquarters Dublin, Dublin |
.
